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Abstract
Background This study aimed to evaluate the additional value of laparoscopic ultrasound (LUS) to staging laparoscopy (SL) for
detecting occult liver metastases in patients with potentially resectable pancreatic head cancer.
Methods A retrospective cohort study was performed including all patients who underwent SL and LUS between 2005 and
2016. LUS was performed during SL to detect liver metastases not found by preoperative imaging or visual inspection of the
liver.
Results Out of 197 patients, visual inspection during SL detected distant metastases in 29 (14.7%) patients. LUS was performed
in 127 patients, revealing 3 additional liver metastases. The proportion of patients with unresectable disease after SL and negative
LUS was 32.3%, which was similar to 36.6% of patients with unresectable disease after SL without LUS (difference 4.3%; 95%
CI − 13–23%; P = 0.61). Sensitivity, specificity, and positive and negative predictive values of LUS to detect liver metastases
were 30, 100, 100, and 94%, respectively. The proportion of patients with distant metastases diagnosed at SL significantly
increased over time (P = 0.031).
Conclusion The routine use of LUS during SL for patients with potentially resectable pancreatic head cancer cannot
be recommended. Imaging should be repeated when significant delay occurs between index CT and the scheduled
surgery.
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Introduction
Pancreatic cancer has a poor prognosis.1,2 Most patients are
not amenable for surgery because of infiltration of local struc-
tures and disseminated disease or because of significant
comorbidities.3 Routine preoperative workup includes com-
puted tomography (CT) to evaluate local resectability and to
exclude disseminated disease.4 Despite this, in approximately
10–25% of patients, locally advanced disease or occult distant
metastases are identified during exploratory laparotomy.5
Staging laparoscopy (SL) may decrease the rate of futile op-
erations in those found to have resectable disease on CT.5,6
SL can be combinedwith laparoscopic ultrasound (LUS) to
allow a detection of occult liver metastases missed by preop-
erative CT. Due to the improvement of imaging techniques
over the last decade, however, the value of LUS in addition
to SL and preoperative CT may have diminished.5,7
Therefore, the aim of this study was to evaluate the additional
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A single-center retrospective analysis was performed of all
patients who underwent SL for suspected pancreatic head or
periampullary cancer at the University Medical Center
Groningen, The Netherlands, between January 2005 and
December 2016. Patients were identified using the internal
database for pancreatic cancer registration in the University
Medical Center Groningen. All patients underwent extensive
preoperative staging including computed tomography (CT)
with iodine contrast. A late arterial phase with a delay of
15 s after bolus tracking and a portal venous phase with a scan
delay of 75 s postinjection was performed. Reconstructions
were made with a slice thickness of 0.75 and 2 mm in the
arterial phase and a slice thickness of 2 mm in the portal
venous phase. All CT scans were assessed by a dedicated
HPB radiologist.
All patients were discussed in our weekly tumor boardmeet-
ing by an interdisciplinary group of hepatopancreatobiliary sur-
geons, radiologists, gastroenterologists, and oncologists. Those
patients with suspected pancreatic head cancer who were con-
sidered potentially resectable and curable were routinely
scheduled for SL. In patients with a history of multiple laparot-
omies or severe lung disease not tolerating a pneumoperitone-
um, SL was contraindicated. In patients with a clear cut preop-
erative diagnosis of cancer of the ampulla of Vater, the duode-
num or the distal bile duct SL was only indicated if indetermi-
nate intra-abdominal lesions were detected on preoperative im-
aging. Patients with an upfront indication for either resection or
(palliative) bypass due to for example subtotal biliary or gastric
outlet obstruction untreatable with endoscopy directly
underwent surgical exploration. Suspicious lesions on imaging
were biopsied preoperatively using percutaneous or endoscopic
ultrasound and reviewed for histological characteristics. This
study was approved by the Ethics Committee of the University
Medical Center Groningen.
Surgical Procedures
SL was performed using an open subumbilical introduction of
a 10-mm trocar for the 30° angled camera. Capnoperitoneum
was established to a pressure of 12–15 mmHg with CO2. One
12-mm trocar was introduced to the left subcostal for the ul-
trasound probe, and one 5-mm trocar was introduced to the
right subcostal. The visceral, parietal, and the left and right
subphrenical peritoneum, diaphragm, lower abdomen, and
ligament of Treitz were routinely inspected for metastases.
The bursa omentalis was left unopened. The liver was visually
inspected on all sides and manipulated using a laparoscopic
retractor to allow inspection of the inferior surface. The
Fig. 1 Flowchart of the outcomes
of patients with potentially
resectable pancreatic head cancer,
who underwent staging
laparoscopy (SL) followed by
laparoscopic ultrasound (LUS) or
not (no LUS)
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ultrasound probe (Hitachi Aloka Medical Ltd., Tokyo, Japan,
Model UST-5550) was introduced, and the liver parenchyma
was visualized systematically. Whenever possible, suspicious
lesions were biopsied and sent to pathology. The definitive
histology of all samples was confirmed postoperatively.
When lesions were not readily accessible for biopsy, new post-
operative imaging and/or ultrasound guided biopsy were per-
formed to confirm metastatic disease. Exploratory laparotomy
was performed when no contraindications were found during
preoperative imaging and SL. Laparotomy was followed by
routine inspection for distant disease and presence of locally
advanced disease. Lesions suspected for metastases were
biopsied immediately and sent for frozen section analysis.
Para-aortic lymph nodes (station 16) and celiac trunk lymph
nodes (station 9) were routinely sampled and sent for frozen
section analysis. Positive lymph nodes were considered a con-
traindication for resection due to reported poor prognosis of this
finding.8 Usually, resection was terminated and palliative dou-
ble bypass was performed. Pancreatoduodenectomy was per-
formed when there was no arterial involvement and/or
untreatable involvement of the superior mesenteric or portal
vein. All patients followed standardized preoperative and post-
operative treatment protocols. All procedures were performed
or supervised by an experienced hepatopancreatobiliary
surgeon.
Statistical Analysis
Statistical analysis was performed with SPSS (version 23.0,
SPSS Inc., Chicago, IL, USA). Normality of distribution was
assessed and checked for skewness. Continuous data were
expressed in medians with interquartile ranges (IQR) and cat-
egorical variables in numbers with percentages. Variables
were compared between the LUS and non-LUS groups using
the Mann-Whitney U test, chi-squared test, and Fisher’s exact
test, where appropriate. A 2 × 2 contingency table and chi-
squared test were used to compare proportions. A two-sided
P value < 0.05 was considered statistically significant.
Results
A total of 518 patients with suspected pancreatic head cancer
were eligible for surgery between January 2005 and
December 2016. Because of aforementioned reasons, 321 pa-
tients directly underwent exploratory laparotomy and were
excluded from analysis. A total of 197 patients underwent
SL prior to exploration. During SL, 29 (14.7%) patients
proved to have distant metastases by visual inspection, of
which 15 patients had liver metastases, 6 with peritoneal me-
tastases, and 8 with liver as well as peritoneal metastases. In
41 patients, no LUS was performed (no LUS group; most
commonly because of adhesions or technical reasons), leaving
127 patients screened by LUS (LUS group; Fig. 1).
The median age of the patients that underwent SL was
67 years. There was a predominance of males (53.3%). The
median time between CT and SL was 52 days. Most patients
that underwent SL were eventually diagnosed with a pancre-
atic ductal adenocarcinoma at definitive pathology (73.4%).
Patient characteristics are presented in Table 1. The median
(IQR) operative time of SLwith and without LUSwas 65 (52–
84) min and 60 (41–128) min, respectively (P = 0.541).
Screening with LUS revealed 3 (2.4%) lesions suspected for
liver metastases that were not detected by preoperative imaging
or visual inspection (Fig. 1). Metastasis was confirmed using
ultrasound-guided percutaneous biopsy in one case and by new
CT imaging in two cases (true positives) (Table 2; Fig. 2). After
SL and LUS, four patients did not undergo subsequent explo-
ration because of worsening patient factors that made them
unfit for explorative laparotomy (Fig. 1).




Age at SL (years), median (IQR) 67 (59–73.5)
Sex: males, n (%) 105 (53.3)
ASA fitness grade, n (%)
- Class I 19 (9.6)
- Class II 130 (66.0)
- Class III 47 (23.9)
- Class IV 1 (0.5)
Ca19-9 (IU/ml), median (IQR) 192 (19-1009)
Preoperative tumor size on CT, n (%)
- No visible tumor 57 (28.9)
- < 20 mm 26 (13.2)
- 20–29 mm 56 (28.4)
- 30–39 mm 35 (17.8)
- ≥ 40 mm 23 (11.7)
Time between CT and SL (days), median (IQR) 52 (37–69)
Operative time SL (min), median (IQR) 64 (49.5–85.0)
Definitive pathology, n (%)
- Pancreatic ductal adenocarcinoma 80 (73.4)
- Distal cholangiocarcinoma 7 (6.4)
- Ampullary carcinoma 5 (4.6)
- Other* 17 (15.6)
Data are given in number with percentages (%) or median with interquar-
tile ranges (IQR)
SL, staging laparoscopy; ASA, American Society of Anesthesiologists;
CT, computed tomography
*Chronic pancreatitis, intraductal papillary mucinous neoplasm, gastro-
intestinal stromal tumor, metastasis of clear cell renal carcinoma, obstruc-
tive stone with fibrosis
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Out of 127 patients who underwent SL and LUS (LUS
group), 120 patients subsequently underwent exploratory lap-
arotomy (Fig. 1). After surgical exploration, seven patients did
not undergo resection due to new found liver metastases (false
negatives). In 30 patients, resection was terminated due to
locally advanced findings such as vascular involvement or
positive distal (para-aortic or celiac trunk) lymph nodes (true
negatives). In 83 patients (65.4%), a pancreatoduodenectomy
was performed (true negatives).
All 41 patients who underwent SL without LUS (no LUS
group) subsequently underwent explorative laparotomy (Fig.
1). After surgical exploration, peritoneal metastases or liver
metastases were found in one and three patients, respectively.
In 11 patients, resection was terminated due to locally ad-
vanced findings or positive distal lymph nodes. In 26 patients,
a pancreatoduodenectomy was performed.
The proportion of patients with unresectable disease after
SL and negative LUS was 32.3% (41 out of 127 patients),
whereas the proportion of patients with unresectable disease
after SL without LUS was 36.6% (15 out of 41 patients). This
resulted in a proportion difference of 4.3% (95% CI − 13–
23%; chi-squared 0.257; 1 df; P = 0.61).
For determination of the effectiveness of LUS as a screen-
ing tool, sensitivity, specificity, positive predicted value
(PPV), and negative predicted value (NPV) were calculated
based on 123 patients with suspected pancreatic head cancer
who underwent SL and LUS and were potentially eligible for
exploratory laparotomy. Sensitivity was 30% (95% CI 6.7–
65%), specificity was 100% (95% CI 97–100%), PPV was
100%, and NPVwas 94% (95%CI 92–96%). After excluding
17 patients whose pathology specimen proved benign, sensi-
tivity was 30% (95% CI 6.7–65%), specificity was 100%
(95% CI 96–100%), PPV was 100%, and NPV was 93%
(95% CI 90–95%).
Because in the three true positive cases the time between CT
and SL was 83, 63, and 70 days, respectively, we calculated the
median time between CT and SL in all 197 patients who
underwent SL. Median time between CT and SL in the 29
patients with metastases detected during SL was 62 days
(IQR 46.5–79 days) versus 51.5 days (IQR 34–68.75 days) in
the 168 patients who were considered resectable after visual
inspection at SL (P = 0.083). When time between CT and SL
was within 30 days, 7.9% of patients showedmetastases during
SL, compared with 12.5% of patients after 60 days, 17.5% of
patients after 90 days, and 29.4% of patients when time be-
tween CT and SL exceeded 90 days (Fig. 3). The proportion
of patients with distant metastases diagnosed at SL significantly
increased over time (P = 0.031).
Discussion
In the present cohort, we found that LUS in addition to SLwas
not of significant additional value to detect radiological occult
liver metastases in patients with potentially resectable pancre-
atic head cancer.
Several studies have investigated LUS as a screening tool
for primary tumor resectability. In these studies, the detection
of distant metastases was a secondary objective. Overall, the
results of these studies have suggested that LUS may improve
the sensitivity to detect liver metastases.9–15
Few studies have investigated the additional value of LUS
compared to modern preoperative imaging modalities.
However, study cohorts were small (n < 50), and only few
Table 2 Case description of positive laparoscopic ultrasound findings
Patient #1 Patient #2 Patient #3
Patient characteristics
Age (years) 57 70 74
Sex Female Male Male
Preoperative findings
Conclusion abdominal CT Only benign lesions seen No abnormalities No abnormalities
Time between CT and SL (days) 83 63 70
Ca19-9 (IU/ml) 112 8266 9269
Operative findings
Results visual inspection with SL One suspect liver lesion No abnormalities No abnormalities
Biopsy taken? Yes, benign – –
Results LUS One additional intrahepatic lesion detected Two lesions detected One lesion detected
Biopsy taken? Not possible Not possible Not possible
Postoperative findings
Follow-up modality Ultrasound-guided percutaneous biopsy CT CT
Conclusion Adenocarcinoma Disseminated disease Disseminated disease
CT, computed tomography; SL, staging laparoscopy; LUS, laparoscopic ultrasound
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patients were diagnosed with occult distant disease (one and
two cases, respectively).16,17 The outcomes of our study are
more in accordance with the results of a larger study in which
the role of intraoperative ultrasound during exploratory lapa-
rotomy was investigated. In less than 1% of 470 patients the
liver metastases found by intraoperative ultrasound resulted in
a significant change of management.18
The two most recently published cohorts regarding this
topic included patients from 2002–2007 to 2005–2008. In
the first study, a historical cohort of 40 patients who
underwent LUS between January 1995 and January 1999
was compared with 9 high-risk patients who underwent LUS
between 2002 and 2007. LUS was only performed on a pool
of patients who fulfilled certain criteria associated with a
higher risk of unresectability, e.g., suspicion of small liver
metastases, signs of peritoneal carcinomatosis or incipient as-
cites, tumors > 4 cm, and lesions of the body and tail, thus
increasing the yield of LUS.19 LUS confirmed preoperative
CT data in eight out of nine patients (seven patients with liver
metastases and one with peritoneal carcinomatosis). In this
subgroup of patients, LUS only would have had additional
value in one case.20 In the second study of 48 patients with
pancreatic head cancer, LUS had additional value in 7 patients
(14.6%), because of mesenteric vein infiltration (4 patients),
involvement of the celiac or para-aortic nodes (2 patients), or
liver metastases (1 patient). All patients preoperatively
underwent staging with biphasic contrast-enhanced CT.16 In
our study, LUS was performed routinely and not for specifi-
cally selected high-risk patients. Furthermore, in our cohort,
all patients were preoperatively staged using tri-phasic CT.
A recent systematic review calculated that the sensitivity,
specificity, PPV, and NPV in previously published studies
were excellent to determine resectability. The two most recent
cohort studies reached a sensitivity, specificity, PPV, and NPV
of 100%.21 However, these calculations were based on studies
that were heterogeneous in resectability criteria, use of multi-
modal imaging protocols, and the quality of CT technology.
More importantly, in the systematic review, sensitivity,
Fig. 3 Absolute number of patients in which distant metastases were
detected or not during staging laparoscopy (SL) categorized by 30-day
intervals following preoperative computed tomography (CT; a). The
proportion of patients with distant metastases diagnosed at SL significant-
ly increased over time (P = 0.031; b)
Fig. 2 Follow-up imaging of the three patients with positive laparoscopic
ultrasound (LUS) findings. The arrows point to the liver metastases found
during LUS. Percutaneous ultrasound showed a 9-mm lesion in liver
segment 4 (a). Computed tomography (CT) confirmed a 10-mm lesion
in liver segment 8 and detected two other lesions of 8 and 13 mm in liver
segment 8 (b). CT demonstrated an 8-mm lesion in liver segment 5 (c)
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specificity, PPV, and NPV were calculated for a combined
yield of SL and LUS,21 whereas in our study, we have studied
the value of LUS in addition to SL for the detection of liver
metastases. This explains the findings of a significantly lower
diagnostic yield in our study.
The current study is the first large series on the addition-
al value of LUS during SL. LUS had diagnostic gain in
only three cases (4%) in addition to abdominal CT and
SL. In all cases, abdominal CT and abdominal ultrasound
confirmed metastatic disease shortly after SL and LUS
(Table 2). Taking the considerable time delay (63 to
83 days) between preoperative CT and SL/LUS into ac-
count, we hypothesize that more recent preoperative imag-
ing would have revealed metastatic disease prior to sur-
gery. Analysis of our data showed that an increasing inter-
val between CT and SL increases the chance that distant
metastases were found during SL. Also, longer intervals
between preoperative imaging and definitive surgery may
have an effect on resectability rates and possible poor sur-
vival. One study demonstrated that the resection rate was
significantly higher when the imaging-to-resection interval
was 32 days or less, when compared to longer waiting
times (87 versus 74%).22 Another recent study described
that the implementation of a fast track pathway without
preoperative biliary drainage for periampullary malignan-
cies leads to a significant reduction in time from index CT
to surgery, when compared to those who had been stented
before referral (16 versus 65 days). In this study, the resec-
tion rate of the group without preoperative biliary drainage
was significantly higher, when compared to that of the not
drained group (97 versus 75%).23 This underlines the im-
portance to perform surgery shortly after the index scan
and to repeat radiological imaging when any delay occurs.
Previous studies have shown that elevated cancer anti-
gen 19-9 levels were associated with an increased yield of
metastatic disease found during SL.24–27 A cancer antigen
19-9 level of 215 U/ml was proposed to select high-risk
patients.24 If this cutoff point would have been applied to
the current series, about half of the patients with distant
metastases would unfairly be excluded for SL (data not
shown). The calculation of an optimal threshold for elevat-
ed cancer antigen 19-9 levels, however, fell beyond the
scope of the current study.
Some limitations need to be taken into consideration. First,
this is a cross-sectional analysis of a cohort study; thus, cause-
effect relationships cannot be established with certainty.
Second, the retrospective design comes with well-known lim-
itations such as selection bias. In our study, we believe this
potential bias was limited because the decision to perform
LUS or not was not made until SL was commenced. We as-
sume that technical errors followed a random pattern and that
severe adhesions were not related to the outcome (i.e., liver
metastases).
In conclusion, our findings demonstrate that with cur-
rent imaging techniques, LUS in addition to SL is of lim-
ited value to detect radiologically occult liver metastases.
Approximately 25 patients with potentially resectable pan-
creatic head cancer need to be screened with LUS during
SL to prevent one additional exploratory laparotomy. With
a sensitivity of only 30%, liver metastases can still be
missed by LUS in a majority of patients. Perhaps, more
important is that repeated imaging should be performed
when significant delay occurs between index CT and the
scheduled surgery.
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